Advertisement

Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

Ropeginterferon, the novel pegylated formulation of interferon alfa-2b, demonstrated efficacy, safety, and tolerability compared with hydroxyurea for the treatment of patients with polycythemia vera, according to research unveiled at the 2017 American Society of Hematology Annual Meeting.

 Targeted Oncology